Table 1.
Physicochemical properties of the formulations.
| Formulation | Size (nm) | PDI | ZP (mV) | Tf CE (%) | Tf μg/mg NPs |
|---|---|---|---|---|---|
| PLGA NPs | 280 ± 35 | 0.146 | − 30 ± 5 | – | – |
| Tf-PLGA NPs | 290 ± 30 | 0.201 | − 21 ± 2* | 79 ± 5 | 7.8 ± 0.5 |
| THC-PLGA NPs | 332 ± 47 | 0.219 | − 35 ± 5 | – | – |
| Tf-THC-PLGA NPs | 284 ± 40 | 0.105 | − 20 ± 3** | 75 ± 6 | 7.4 ± 0.6 |
| FITC-PLGA NPs | 316 ± 38 | 0.179 | − 18 ± 4** | – | – |
| Tf-FITC-PLGA NPs | 260 ± 35 | 0.119 | − 15 ± 2*** | 61 ± 6 | 6.1 ± 0.6 |
| NR-FITC-PLGA NPs | 288 ± 30 | 0.209 | − 20 ± 2** | – | – |
| Tf-NR-FITC-PLGA NPs | 289 ± 19 | 0.106 | − 14 ± 1**** | 65 ± 4 | 6.4 ± 0.4 |
| Rh-FITC-PLGA NPs | 282 ± 32 | 0.153 | − 19 ± 4** | – | – |
| Tf- Rh-FITC-PLGA NPs | 302 ± 38 | 0.113 | − 15 ± 2*** | 51 ± 5 | 5.1 ± 0.5 |
Tf CE Tf conjugation efficacy. Statistically significant differences in ZP values are referred to plain PLGA NPs as control group; *p < 0.0332; **p < 0.0021; ***p < 0.0002; ****p < 0.0001.